000
| 01579nam 2200289za 4500 |
---|
001 | 9.573626 |
---|
003 | CaOODSP |
---|
005 | 20210624183805 |
---|
007 | cr ||||||||||| |
---|
008 | 150406t19981997cn ad|||o f000 0 eng d |
---|
020 | |a0-662-26385-5 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aH42-2/67-12-1997E-PDF |
---|
245 | 00|aGeneral considerations for clinical trials |h[electronic resource]. |
---|
246 | 3 |iAt head of title: |aICH Harmonised Tripartite guideline : |bInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
---|
260 | |aOttawa : |bTherapeutic Products Directorate, Health Canada. |c1998, c1997. |
---|
300 | |aii, 22 p. : |bill. |
---|
490 | 1 |aTherapeutic Products Directorate guidelines |
---|
500 | |a"ICH Harmonised Tripartite guideline, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use." |
---|
500 | |aIncorrect catalogue number (H42-2/67-12-1997IN) recorded in this electronic publication. |
---|
590 | |a12-14-Supp|b2012-04-10 |
---|
710 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Directorate. |
---|
775 | 08|tConsidérations générales relatives aux études cliniques : |w(CaOODSP)9.603737 |
---|
776 | 0#|tICH harmonized tripartite guideline: general consideration for clinical trials : |w(CaOODSP)9.614224 |
---|
830 | #0|aTherapeutic Products Directorate guidelines.|w(CaOODSP)9.506920 |
---|
856 | 40|ahttp://publications.gc.ca|qPDF|s105 KB|uhttps://publications.gc.ca/collections/Collection/H42-2-67-12-1997E.pdf |
---|